DE3036131A1 - Neue desoxycytidin-verbindungen, deren herstellung und diese enthaltende pharmazeutische zubereitungen - Google Patents
Neue desoxycytidin-verbindungen, deren herstellung und diese enthaltende pharmazeutische zubereitungenInfo
- Publication number
- DE3036131A1 DE3036131A1 DE19803036131 DE3036131A DE3036131A1 DE 3036131 A1 DE3036131 A1 DE 3036131A1 DE 19803036131 DE19803036131 DE 19803036131 DE 3036131 A DE3036131 A DE 3036131A DE 3036131 A1 DE3036131 A1 DE 3036131A1
- Authority
- DE
- Germany
- Prior art keywords
- deoxycytidine
- halovinyl
- compounds
- compound according
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 12
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 55
- -1 deoxycytidine compound Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- JUYRSVVLNGQWBD-PIXDULNESA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidin-2-one Chemical group C1=C(\C=C\I)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 JUYRSVVLNGQWBD-PIXDULNESA-N 0.000 claims description 11
- AKVDSWDYVDOWDW-PIXDULNESA-N 4-amino-5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical group C1=C(\C=C\Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 AKVDSWDYVDOWDW-PIXDULNESA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 229940104302 cytosine Drugs 0.000 claims description 5
- XTSXCWQFTSJRAG-BJPDOBEOSA-N ethyl (e)-3-[4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-5-yl]prop-2-enoate Chemical compound O=C1N=C(N)C(/C=C/C(=O)OCC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XTSXCWQFTSJRAG-BJPDOBEOSA-N 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- JEEPLDNEMJPHTF-PIXDULNESA-N (e)-3-[4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-5-yl]prop-2-enoic acid Chemical compound C1=C(\C=C\C(O)=O)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 JEEPLDNEMJPHTF-PIXDULNESA-N 0.000 claims description 3
- PDWIQYODPROSQH-PYHARJCCSA-N 2-deoxy-D-ribofuranose Chemical class OC[C@H]1OC(O)C[C@@H]1O PDWIQYODPROSQH-PYHARJCCSA-N 0.000 claims description 3
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 3
- OUFFZTAHNSOGKX-UHFFFAOYSA-L dichloropalladium;lithium Chemical compound [Li].Cl[Pd]Cl OUFFZTAHNSOGKX-UHFFFAOYSA-L 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 description 25
- 241000700605 Viruses Species 0.000 description 22
- 230000000840 anti-viral effect Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 241000700584 Simplexvirus Species 0.000 description 9
- 208000009889 Herpes Simplex Diseases 0.000 description 8
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002140 halogenating effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 241001342522 Vampyrum spectrum Species 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 230000026030 halogenation Effects 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- FHSISDGOVSHJRW-UHFFFAOYSA-N 5-formylcytosine Chemical compound NC1=NC(=O)NC=C1C=O FHSISDGOVSHJRW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- DHEWADWIHJATHC-OWOJBTEDSA-N (e)-3-(6-amino-2-oxo-1h-pyrimidin-5-yl)prop-2-enoic acid Chemical compound NC1=NC(=O)NC=C1\C=C\C(O)=O DHEWADWIHJATHC-OWOJBTEDSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
- ZRYZBEQILKESAW-UHFFFAOYSA-N 5-ethenyl-1h-pyrimidine-2,4-dione Chemical compound C=CC1=CNC(=O)NC1=O ZRYZBEQILKESAW-UHFFFAOYSA-N 0.000 description 1
- WPIODDDSOONWLM-UHFFFAOYSA-N 6-amino-5-ethenyl-1h-pyrimidin-2-one Chemical compound NC1=NC(=O)NC=C1C=C WPIODDDSOONWLM-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 241000786363 Rhampholeon spectrum Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- LTKCXZGFJFAPLY-OERIEOFYSA-N [1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]azanium;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LTKCXZGFJFAPLY-OERIEOFYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RQRCSGINRYPWLV-IMSIIYSGSA-N ethyl 3-[(2s,4s,5r)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]prop-2-enoate Chemical compound C1=CC(N)=NC(=O)N1[C@@]1(C=CC(=O)OCC)C[C@H](O)[C@@H](CO)O1 RQRCSGINRYPWLV-IMSIIYSGSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7934248A GB2060604B (en) | 1979-10-03 | 1979-10-03 | E15-(2-halogenovinyl)-2'-deoxycytidines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3036131A1 true DE3036131A1 (de) | 1981-04-16 |
| DE3036131C2 DE3036131C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-07-06 |
Family
ID=10508255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803036131 Granted DE3036131A1 (de) | 1979-10-03 | 1980-09-25 | Neue desoxycytidin-verbindungen, deren herstellung und diese enthaltende pharmazeutische zubereitungen |
Country Status (11)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988004662A1 (en) * | 1986-12-19 | 1988-06-30 | Astra Läkemedel Aktiebolag | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus |
| US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199764A (en) * | 1981-03-20 | 1984-08-24 | Beecham Group Plc | 5-(2-halogenovinyl)-2'-deoxyuridine derivatives and pharmaceutical compositions |
| HU183567B (en) * | 1981-09-07 | 1984-05-28 | Mta Koezponti Kemiai Kutato In | Process for preparing /e/-5-/2-bromo-vinyl/-uridine and derivatives thereof |
| JPS5843993A (ja) * | 1981-09-09 | 1983-03-14 | Yamasa Shoyu Co Ltd | １−β−Ｄ−アラビノフラノシル−（Ｅ）−５−（２−ハロゲノビニル）ウラシル−５′−りん酸およびその製造法 |
| EP0080305A1 (en) * | 1981-11-19 | 1983-06-01 | Beecham Group Plc | Antiviral 2'-deoxyuridines, their preparation and use |
| EP0082668A1 (en) * | 1981-12-18 | 1983-06-29 | Beecham Group Plc | 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections |
| US4782142A (en) * | 1982-01-05 | 1988-11-01 | The Research Foundation Of State University Of New York | Novel 5-substituted 2-pyrimidinone nucleosides and methods of use |
| FI832884L (fi) * | 1982-08-17 | 1984-02-18 | Sandoz Ag | Desoxiuridinderivat, deras framstaellningsfoerfaranden och anvaendning som farmaceutiska medel |
| ES525670A0 (es) * | 1982-09-17 | 1985-02-01 | Glaxo Group Ltd | Un procedimiento para preparar derivados de 5-halovinil-2'-desoxiuridina |
| US4666892A (en) * | 1984-03-06 | 1987-05-19 | Sloan-Kettering Memorial Cancer Center | Method and composition for hepatitis treatment with pyrimidine nucleoside compounds |
| AU575918B2 (en) * | 1984-03-06 | 1988-08-11 | Sloan-Kettering Institute For Cancer Research | Hepatitis treatment with pyrimidine nucleoside compounds |
| US4762823A (en) * | 1985-10-16 | 1988-08-09 | Sloan-Kettering Institute For Cancer Research | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil |
| WO1990001324A1 (en) * | 1988-08-10 | 1990-02-22 | Stephen Leslie Sacks | PRODUCTION OF RADIOIODINATED 1-β-D-ARABINOFURANOSYL)-5(E)-(2-IODOVINYL)URACIL, AND USES THEREOF, AND RELATED ANALOGUES INCORPORATING ALTERNATIVE HALOGEN RADIONUCLIDES, THE GENERAL RADIOHALOGENATION PRECURSORS, 1-(2,3,5-TRI-O-ACETYL-β-D-ARABINOFURANOSYL)-5(Z and E)-(2-TRIMETHYLSILYLVINYL)URACIL, PROCESSES FOR RADIOHA |
| KR100893549B1 (ko) | 2000-03-29 | 2009-04-17 | 조지타운 유니버시티 | 델타형 간염 바이러스 감염의 치료방법 |
| US7211570B2 (en) * | 2001-12-20 | 2007-05-01 | Pharmasset, Inc. | Treatment of EBV and KHSV infection |
| JP2008174524A (ja) * | 2007-01-22 | 2008-07-31 | Nippon Shinyaku Co Ltd | リボ核酸化合物の製造方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354160A (en) * | 1965-07-22 | 1967-11-21 | Hoffmann La Roche | Tri-lower alkyl-silyl-5-fluoropyrimidines |
| US4000260A (en) * | 1974-08-29 | 1976-12-28 | Research Corporation | Anti herpes simplex viral compounds and their synthesis |
| US4024143A (en) * | 1976-03-11 | 1977-05-17 | Pcr, Inc. | Silylation of 5-fluoro-6-hydroxy or alkoxy pyrimidine |
| US4267171A (en) * | 1979-07-02 | 1981-05-12 | The Regents Of The University Of California | C-5 Substituted cytosine nucleosides |
-
1979
- 1979-10-03 GB GB7934248A patent/GB2060604B/en not_active Expired
-
1980
- 1980-09-24 NL NL8005336A patent/NL8005336A/nl not_active Application Discontinuation
- 1980-09-24 SE SE8006669A patent/SE445740B/sv not_active IP Right Cessation
- 1980-09-25 DE DE19803036131 patent/DE3036131A1/de active Granted
- 1980-09-25 CH CH7181/80A patent/CH647245A5/de not_active IP Right Cessation
- 1980-09-26 BE BE1/9967A patent/BE885415A/nl not_active IP Right Cessation
- 1980-10-02 US US06/193,251 patent/US4382925A/en not_active Expired - Lifetime
- 1980-10-02 FR FR8021170A patent/FR2466472A1/fr active Granted
- 1980-10-02 JP JP13861580A patent/JPS5695198A/ja active Granted
- 1980-10-02 IT IT8009551A patent/IT1209758B/it active
- 1980-10-03 CA CA000361953A patent/CA1173438A/en not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS ERMITTELT * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988004662A1 (en) * | 1986-12-19 | 1988-06-30 | Astra Läkemedel Aktiebolag | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus |
| US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1173438A (en) | 1984-08-28 |
| FR2466472B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1983-12-23 |
| IT1209758B (it) | 1989-08-30 |
| GB2060604A (en) | 1981-05-07 |
| IT8009551A0 (it) | 1980-10-02 |
| JPS637199B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-02-15 |
| DE3036131C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-07-06 |
| NL8005336A (nl) | 1981-04-07 |
| BE885415A (nl) | 1981-03-26 |
| FR2466472A1 (fr) | 1981-04-10 |
| US4382925A (en) | 1983-05-10 |
| CH647245A5 (de) | 1985-01-15 |
| SE8006669L (sv) | 1981-04-04 |
| GB2060604B (en) | 1983-11-23 |
| JPS5695198A (en) | 1981-08-01 |
| SE445740B (sv) | 1986-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2915254C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3036131C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3785651T2 (de) | Antivirale Verbindungen. | |
| DE3854110T2 (de) | 2'-alkyliden-pyrimidin-nukleosid-derivate, verfahren zur herstellung und verwendung. | |
| DE2056327C2 (de) | 2,6-Diamino-9-(β-D-arabinofuranosyl)-purin, dessen N-6-Niedrigalkylderivate, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, welche diese Verbindungen enthalten | |
| DE2166717A1 (de) | Verfahren zur herstellung von arabinofuranosylverbindungen | |
| DE3390162T1 (de) | Desoxyuridinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika | |
| DE2722032A1 (de) | 9-(3,5-di-o-acyl-beta-d-arabinofuranosyl)-adenin-verbindungen | |
| DE2552293A1 (de) | Antileukaemische verbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| EP0255894B1 (de) | Pyrimidinderivate, deren Herstellung und Arzneimittel, die diese Derivate enthalten | |
| DE68914750T2 (de) | Therapeutische Nucleoside. | |
| DD296081A5 (de) | Verfahren zur herstellung antibiotischer verbindungen | |
| DE2310329A1 (de) | Arabinofuranosylcytosine und verfahren zu ihrer herstellung | |
| CH653340A5 (de) | (e)-5-(2-bromvinyl)-uridine und verfahren zu ihrer herstellung. | |
| DE2722031A1 (de) | 9-(2-o-acyl-beta-d-arabinofuranosyl)- adenin-verbindungen | |
| EP0256400A2 (de) | Pyrimidinderivate, ihre Herstellung und Medikamente die diese Derivate enthalten | |
| DE69008085T2 (de) | Oxetanocinderivate, ihre Salze und ihre Verwendung. | |
| DE3820588C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2817923C2 (de) | Septacidinverbindungen und diese enthaltende Arzneimittel | |
| DE68928127T2 (de) | 2'-Methylidenpyrimidinnukleosidverbindungen, ihre Verwendung und Verfahren zu ihrer Herstellung | |
| DE69915327T2 (de) | Derivate des erythromycins, des clarithromycins, des roxithromycins oder des azithromycin mit antibiotischer und mucolytischer wirkung | |
| DE1620185B2 (de) | 5-Äthyl- und 5-Propyl-2'-deoxyuridin, Verfahren zur Herstellung dieser Verbindungen und diese Verbindungen enthaltende Arzneim ittel | |
| EP0139859B1 (de) | 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| DE2722096A1 (de) | 9-(5-0-acyl-beta-d-arabinofuranosyl)- adenin-verbindungen | |
| CH660740A5 (de) | Halogenanthracyclinglykoside. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8180 | Miscellaneous part 1 |
Free format text: DER ANMELDER LAUTET RICHTIG THE UNIVERSITY OF BIRMINGHAM, BIRMINGHAM, WARWICKSHIRE, GB STICHTING REGA V.Z.W., LEUVEN, BE |
|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: SCHOENWALD, K., DR.-ING. FUES, J., DIPL.-CHEM. DR. |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |